# The next level in RNA/DNA diagnostics

> At the heart of Cube Dx’s proprietary RNA/DNA technology lie the **hybcell** and **compact sequencing** – an ultra-sensitive PCR process followed by highly specific resolution of several hundred RNA or DNA targets. Robust, fast, efficient.

## Hundreds of answers from one sample
The pan-bacterial 16S and pan-fungal 28S PCR separates negative from positive results. Positive samples are then examined in parallel against many targets on the cylindrical hybcell and read out in under 20 minutes.
- Massively parallel multiplexing in the smallest space
- Short, cost-effective protocol for negative samples — no ID necessary
- One technology platform, many fields of application

### Earlier to result
Comprehensive pathogen ID directly from whole blood and other sample matrices in less than 3 hours — no culturing required.

### Additional results
Additional results from DNA-based detection of pathogens that are difficult to culture (fungi, fastidious bacteria, anaerobes) or for patients who have already undergone treatment.

### Versatile multiplexing
Sepsis, other severe infections (pneumonia, etc.), or general 16S/28S amplicon sequencing—the same platform, the same products, multiple applications.

The innovative hybcell technology and compact sequencing deliver fast and reliable pathogen ID for effective treatment — right from the start. The first direct whole-blood test was introduced in 2020 and has been in clinical routine ever since.

The underlying compact sequencing technology and the innovative sample-preparation methods were developed by cube dx. The products can be used in a comprehensive workflow or standalone for well-defined applications such as 16S amplicon sequencing.